| Project/Area Number |
22650223
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Carcinogenesis
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HOSONO Osamu 東京大学, 医科学研究所, 講師 (50190210)
IWATA Satoshi 東京大学, 医科学研究所, 特任講師 (00396871)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,320,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2010: ¥1,500,000 (Direct Cost: ¥1,500,000)
|
|---|
| Keywords | がん幹細胞 / エピジェネティックス / B-ALL / 悪性中皮腫 / CD9 / CD24 / CD26 / USP22 / 癌幹細胞 / シグナル伝達 / ノックダウン / RNAi / ヒストン脱ユビキチン酵素 / がん / エピジェネティック / 表面抗原マーカー / CD34 |
|---|
| Research Abstract |
In the current study, we performed more detailed analysis of CD9 function for the cancer stem cell properties of B-ALL. In patient samples, CD9 was expressed in the most cases of B-ALL cells with significant correlation of CD34-expression. Knockdown of CD9 remarkably reduced the leukemogenic potential and affected the expression and tyrosine phosphorylation of Src family protein and reduced the expression of histone-deubiquitinase USP22. In malignant mesothelioma our results showed that CD24 and CD26 differentially regulated the cancer stem cell potentials of MM and also CD26 expression closely correlated with expression of USP22. These results suggest that CD24, CD9 and CD26 could be the promising target for CSC-oriented therapy.
|
